title: Do patients on alpha-blockers for the treatment of benign prostatic hyperplasia have better results after shockwave lithotripsy of urinary stones?
abstract: OBJECTIVE
  To investigate whether patients who are on alpha 1-adrenergic receptor (alpha 1-AR) antagonists for the treatment of benign prostatic hyperplasia (BPH) had better results after extracorporeal shockwave lithotripsy (SWL).
  
  
  METHODS
  We retrospectively reviewed the records of male patients older than 50 years who underwent SWL. Clinical characteristics, including the use of alpha 1-AR antagonists for BPH were analyzed. Mann-Whitney U test was used for data not normally distributed and student's t test for data normally distributed. The categorical variables were analyzed by the Chi-square test. A multiple logistic regression analysis was used to analyze the associations of variables on successful treatment.
  
  
  RESULTS
  A total of 264 renal units were treated. Complete stone clearance was achieved in 167 RUs (63.3%) and 28 RUs (10.6%) had clinically insignificant residual fragments. In 69 RUs (26.1%), SWL failed. More patients were on alpha 1-AR antagonists for BPH in the successfully treated group (p=0.028). The multivariate analysis revealed that the use of alpha 1-AR antagonists had significant effects on the success of SWL (p=0.047). SWL was performed to 34 RUs of 33 patients who were on alpha 1-AR antagonists and it was successful in 30 RUs (88.2%). In the remaining 230 RUs, stone-free state was achieved in 165 RUs (71.7%) (p=0.028). Stone-free rates were similar for patients on alfuzosine, tamsulosine, and doxazosine (p=0.310).
  
  
  CONCLUSIONS
  Patients who are being treated with alpha 1-AR antagonist agents for BPH have better results after SWL treatment, compared to patients not receiving alpha 1-AR antagonist. The improved results are independent of the type of alpha 1-AR antagonist.
authors.affiliation: Department of Urology, Faculty of Medicine, Baskent University, Ankara, Turkey . umitgul@yahoo.com
authors.forename: Umit
authors.initials: U
authors.lastname: Gul
authors.forename: Ozgur
authors.initials: O
authors.lastname: Yaycıoglu
authors.forename: Baris
authors.initials: B
authors.lastname: Kuzgunbay
authors.forename: Cagla
authors.initials: C
authors.lastname: Sarıturk
authors.forename: Mehmet Vehbi
authors.initials: MV
authors.lastname: Kayra
authors.forename: Hakan
authors.initials: H
authors.lastname: Ozkardes
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D006801:Humans; D008096:Lithotripsy; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014545:Urinary Calculi / Q000150:complications* / Q000628:therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists